- ￥364
- Cayman
- 美国
- 14010-1 mg
- 2025年07月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名：
Prostaglandin E2
- CAS号：
363-24-6
- 保质期：
365
- 保存条件：
-20
- 库存：
大量
- 供应商：
欣博盛
- 规格：
1 mg
品牌： Cayman
产品货号： 14010
规格：多规格，可咨询代理商欣博盛生物
PGE2 is one of the primary COX products of arachidonic acid (Item No. 90010) and one of the most widely investigated prostaglandins. Its activity influences inflammation, fertility and parturition, gastric mucosal integrity, and immune modulation.1,2,3,4 The effects of PGE2 are transduced by at least four distinct receptors designated EP1, EP2, EP3, and EP4.5 Af-finity constants (Kd) of PGE2 for these receptors range from 1-10 nM depending on the receptor subtype and tissue.
产品信息：
CAS号：363-24-6
分子式：C20H32O5
分子量：352.5
纯度：≥98%
形式：固体
储存：-20℃
稳定性：≥2年
产品介绍：
Prostaglandin E2是花生四烯酸(90010号)的主要环加氧酶产物之一，也是研究最广泛的PGs之一。它的活性影响炎症、生育和分娩、胃粘膜完整性和免疫调节。4 -4 PGE的作用，由至少四种不同的受体转导，分别是EP、、EP、EP和EP。5这些受体的亲和力常数(K)范围在1-10 nM，取决于受体的亚型和组织。
如需购买相关产品，请联系Cayman中国授权代理商欣博盛生物。
Technical Information
Formal Name
9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid
CAS Number
363-24-6
Synonyms
Dinoprostone
PGE2
Molecular Formula
C20H32O5
Formula Weight
352.5
Purity
≥98%
Formulation
(Request formulation change)
A crystalline solid
Solubility
(Learn about Variance in Solubility)
DMF: >100 mg/ml
DMSO: >100 mg/ml
Ethanol: >100 mg/ml
PBS pH 7.2: 5 mg/ml
SMILES
O=C1[C@H](C/C=C\CCCC(O)=O)[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C1
InChi Code
InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
InChi Key
XEYBRNLFEZDVAW-ARSRFYASSA-N
Origin
Synthetic
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Stability
≥ 2 years
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验1. Willis, A.L., and Cornelsen, M. Repeated injection of prostaglandin E2 in rat paws induces chronic swelling and a marked decrease in pain threshold. Prostaglandins 3(3), 353-357 (1973).
2. Jackson, G.M., Sharp, H.T., and Varner, M.W. Cervical ripening before induction of labor: A randomized trial of prostaglandin E2 gel versus low-dose oxytocin. Am. J. Obstet. Gynecol. 171(4), 1092-1096 (1994).
3. Robert, A., Schultz, J.R., Nezamis, J.E., et al. Gastric antisecretory and antiulcer properties of PGE2, 15-me-thyl PGE2, and 16,16-dime-thyl PGE2. Intravenous, oral and intrajejunal administration. Gastroenterology 70(3), 359-370 (1976).
4. Arvind, P., Papavassiliou, E.D., Tsioulias, G.J., et al. Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 34(16), 5604-5609 (1995).
5. Coleman, R.A., Smith, W.L., and Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46(2), 205-229 (1994).
Product Citations
Pang, Y., Liu, X., Zhao, C., et al. LC-MS/MS-based arachidonic acid metabolomics in acute spinal cord injury reveals the upregulation of 5-LOX and COX-2 products. Free Radic. Biol. Med. 193(Pt 1), 363-372 (2022).
Archambault, A.-S., Brassard, J., Bernatchez, É., et al. Human and mouse eosinophils differ in their ability to biosynthesize eicosanoids, docosanoids, the endocannabinoid 2-arachidonoyl-glycerol and its congeners. Cells 11(1), 141 (2022).
Archambault, A.-S., Zaid, Y., Rakotoarivelo, V., et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J. 35(6), e21666 (2021).
Roberts, L.M., Schwarz, B., Speranza, E., et al. Pulmonary infection induces persistent, pathogen-specific lipidomic changes influencing trained immunity. iScience 24(9), 103025 (2021).
Wang, Y., Cui, L., Georgiev, P., et al. Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor ef-ficacy by modulating both lymphocytes and myeloid cells. Oncoimmunology 10(1), 1896643 (2021).
Hartling, I., Cremonesi, A., Osuna, E., et al. Quantitative profiling of inflammatory and pro-resolving lipid mediators in human adolescents and mouse plasma using UHPLC-MS/MS. Clin. Chem. Lab. Med. 59(11), 1811-1823 (2021).
Archambault, A.-S., Zaid, Y., Rakotoarivelo, V., et al. Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites. medRxiv (2020).
Endo, S., Suganami, A., Fukushima, K., et al. 15-Keto-PGE2 acts as a biased/partial agonist to terminate PGE2-evoked signaling. The Journal of Biological Chemisty 295(38), 13338-13352 (2020).
Meriwether, D., Sulaiman, D., Volpe, C., et al. Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J. Clin. Invest. 130, 3670-3685 (2019).
Schmidleithner, L., Thabet, Y., Schönfeld, E., et al. Enzymatic activity of HPGD in Treg cells suppresses Tconv cells to maintain adipose tissue homeostasis and prevent metabolic dysfunction. Immunity 50(5), 1232-1248 (2019).
Saldaña, L., Bensiamar, F., Vallés, G., et al. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. Stem Cell Res. Ther. 10(1), 58 (2019).
Chen, I.-J., Hee, S.-W., Liao, C.-H., et al. Targeting the 15-keto-PGE2-PTGR2 axis modulates systemic inflammation and survival in experimental sepsis. Free Radic. Biol. Med. 115, 113-126 (2018).
Allain, E.P., Rouleau, M., Le, T., et al. In activation of prostaglandin E2 as a mechanism for UGT2B17-mediated adverse effects in chronic lymphocytic leukemia. Front. Oncol. 9:606, (2019).
Dalli, J., Colas, R.A., Walker, M.E., et al. Lipid Mediator Metabolomics via LC-MS/MS Profiling and Analysis. Clinical Metabolomics 59-72 (2018).
Sorgi, C.A., Peti, A.P.F., Petta, T., et al. Comprehensive high-resolution multiple-reaction monitoring mass spectrometry for targeted eicosanoid assays. Sci. Data 5, 180167 (2018).
Ho, A.T.V., Palla, A.R., Blake, M.R., et al. Prostaglandin E2 is essential for ef-ficacious skeletal muscle stem-cell function, augmenting regeneration and strength. Proc. Natl. Acad. Sci. USA 114(26), 6675-6684 (2017).
Suganami, A., Fujino, H., Okura, I., et al. Human DP and EP2 prostanoid receptors take on distinct forms depending on the diverse binding of different ligands. FEBS J. 283(21), 3931-3940 (2016).
Hennebelle, M., Zhang, M., Metherel, A.H., et al. Linoleic acid participates in the response to ischemic brain injury through oxidized metabolites that regulate neurotransmission. Sci. Rep. 7(4342), (2017).
Venerito, M., Helmke, C., Jechorek, D., et al. Leukotriene receptor expression in esophageal squamous cell cancer and non-transformed esophageal epithelium: a matched case control study. BMC Gastroenterol. 16(1), 85 (2016).
Sasaki, A., Fukuda, H., Shiida, N., et al. Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS. Anal. Bioanal. Chem. 407(6), 1625-1639 (2015).
Otake, S., Yoshida, K., Seira, N., et al. Cellular density-dependent fown-regulation of EP4 prostanoid receptors via the up-regulation of hypoxia-inducible factor-1a in HCA-7 human colon cancer cells. Pharm. Res. Prespect. 3(1), e00083 (2014).
Qi, H.-Y., Daniels, M.P., Liu, Y., et al. A cytosolic phospholipase A2-initiated lipid mediator pathway induces autophagy in macrophages. J. Immunol. 187(10), 5286-5292 (2011).
Wobst, I., Schiffmann, S., Birod, K., et al. Dime-thylcelecoxib inhibits prostaglandin E2 production. Biochem. Pharmacol. 76(1), 62-69 (2008).
George, R.J., Sturmoski, M.A., Anant, S., et al. EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat. 83(1-2), 112-120 (2007).
Fujino, H., and Regan, J.W. EP4 prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol. Pharm. 69(1), 5-10 (2006).
Zhong, H., Willard, M., and Simons, J. NS398 reduces hypoxia-inducible factor (HIF)-1a and HIF-1 activity: Multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int. J. Cancer 112, 585-595 (2004).
Woodward, D.F., Krauss, A.H.P., Chen, J., et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305(2), 772-785 (2003).
Levy, B.D., De Sanctis, G.T., Devchand, P.R., et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med. 8(9), 1018-1023 (2002).
技术资料暂无技术资料 索取技术资料
